Overview

Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

In a double-blind, randomized controlled trial, we assigned PLWH receiving ART without a history of cardiovascular events to received colchicine 0.6 mg once daily or placebo. The primary endpoint was the mean difference of hs-CRP, IL-6, and IL-1 Ra levels at three and six months. The secondary endpoint was to access safety outcomes.

Phase:

Phase 4

Details

Lead Sponsor:

Mahidol University

Collaborator:

Thai AIDs society

Treatments:

Colchicine